CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


ATAFENOVIR 200 MG KAPSULWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug88 ARBIDOL 100 MG KAPSUL Wiki 1.00
drug2507 SBI-101 Wiki 1.00

Correlated MeSH Terms (2)


Name (Synonyms) Correlation
D058186 Acute Kidney Injury NIH 0.23
D014947 Wounds and Injuries NIH 0.19

Correlated HPO Terms (1)


Name (Synonyms) Correlation
HP:0001919 Acute kidney injury HPO 0.23

There is one clinical trial.

Clinical Trials


1 Open-Label, Randomised, Single Oral Dose, Two-Period, Cross-Over Trial To Assess The Bioequivalence Of Atafenovir 200 Mg Kapsul In Comparison With Arbidol 100 Mg Kapsul In Healthy Male Subjects Under Fasting Conditions

A single dose of Reference product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride and a single dose of Test product containing 200 mg umifenovir hydrochloride monohydrate equivalent to 200 mg umifenovir hydrochloride or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with Covid-19 Pandemic precautions.

NCT04476719 Bioequivalence Drug: ATAFENOVIR 200 MG KAPSUL Drug: ARBIDOL 100 MG KAPSUL

Primary Outcomes

Description: AUC0-tlast umifenovir

Measure: Primary PK Endpoint

Time: 12 weeks

Description: Cmax of umifenovir

Measure: Primary PK Endpoint

Time: 13 weeks

Secondary Outcomes

Description: t1/2 of umifenovir

Measure: Secondary PK Endpoint

Time: 14 weeks

Description: tmax of umifenovir

Measure: Secondary PK Endpoint

Time: 15 weeks

Description: AUC0-inf of umifenovir

Measure: Secondary PK Endpoint

Time: 16 weeks


No related HPO nodes (Using clinical trials)